California
Biotech Insights

M&A, Deals, Partnerships: Genentech (SF) Inks Up-to-$1.5B Bispecific Antibody Pact with Earendil Labs Genentech is paying $55M upfront, with up to $1.445B in development, regulatory and sales milestones plus tiered royalties, for a research collaboration on AI-designed bispecific antibodies against pre-agreed oncology target combinations. Earendil leads antibody discovery and early clinical research; Genentech takes over […]

Recent Funding: Circle Pharma (SF) raises $92.5M Series E for first-in-class cyclin D1 program Closed an oversubscribed $92.5 million Series E led by The Column Group, with RA Capital, Nextech, Euclidean and Eli Lilly participating. Funds advance CID-165, an oral macrocyclic cyclin D1 inhibitor, toward a Q1 2027 clinical start in ER-positive breast cancer. M&A, […]

Recent Funding: Encoded Therapeutics (SF) closes $275M Series F for Dravet syndrome gene therapy   Closed a $275 million Series F backed by GV, ARCH Venture Partners, SoftBank Vision Fund 2 and others to fund a pivotal study of ETX101, its gene therapy for SCN1A-positive Dravet syndrome in infants and young children. Proceeds also scale internal […]

Recent Funding: Moonwalk Biosciences (SF) Raises $70M Series B to Test siRNA Obesity Treatment The genomic biotech closed a $70 million Series B co-led by Alpha Wave and YK Bioventures, with Eli Lilly, Gaorong Ventures, ARCH Venture Partners, Khosla Ventures and Future Ventures participating. Proceeds will move lead obesity candidate MW101 — an adipose-targeted RNAi […]

Recent Funding: AusperBio (SF) Completes $120M Series C to Advance Hepatitis B Oligonucleotide Toward Commercialization  Raised a $120M Series C led by RA Capital Management (with Qiming, HanKang, YuanBio, CDH and others) to push lead antisense oligonucleotide AHB-137 through Phase 3 and toward commercialization. AHB-137 is an unconjugated ASO designed to suppress hepatitis B viral […]

M&A, Deals, Partnerships: BioMarin (SF) Buys Alesta for $275M to Enter Rare Bone Disease Acquiring Alesta Therapeutics for $275M upfront plus up to $215M in milestones to gain ALE1, an oral small molecule for hypophosphatasia (a rare genetic bone disease), setting up a challenge to AstraZeneca’s enzyme therapy. ALE1 is in a Phase 1/2a trial; […]